Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,188 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,266 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06301399 | Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06628661 | Ten-Year Outcomes of Operable Solitary Hepatocellular Carcinoma Patients: Impact of Tumor Size Over 6.5 cm and Microvascular Invasion | recruiting | — | 3,000 | Chang Gung Memorial HospitalOTHER | 1 | Nov 20, 2024 |
| clinicaltrials |
| NCT06694636 | Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma | recruiting | N/A | 5 | Zhongda HospitalOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06313190 | Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)(HSBRT2402) | recruiting | Phase 2 | 140 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05072041 | Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma | recruiting | N/A | 150 | Next Biomedical Co., Ltd.INDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT03024684 | Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment(SHOT) | active not recruiting | Phase 4 | 240 | Chiayi Christian HospitalOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT05887661 | Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy | recruiting | N/A | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06682377 | Radiofrequency Ablation Using Combined RF Energy Delivery Mode and Octopus Electrodes for Hepatocellular Carcinoma(SM-OCT-01) | active not recruiting | N/A | 159 | Seoul National University HospitalOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06685354 | Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study | not yet recruiting | Phase 2 | 11 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06341764 | Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma | recruiting | Phase 2 | 38 | National Cancer Institute, NaplesOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06461624 | Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 15 | Zhejiang UniversityOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT05595473 | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma | active not recruiting | Phase 1 / Phase 2 | 42 | Rznomics, Inc.OTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06595108 | Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma(A-BEST) | recruiting | N/A | 33 | Yonsei UniversityOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06669377 | TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT. | recruiting | — | 444 | Zhongda HospitalOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06670547 | Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography | not yet recruiting | — | 3,000 | Germans Trias i Pujol HospitalOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT06664996 | Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT | recruiting | Phase 2 | 33 | West China HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06662877 | Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment | not yet recruiting | Phase 2 / Phase 3 | 206 | Sun Yat-sen UniversityOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06611345 | A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers | recruiting | N/A | 60 | Jiangsu Healthy Life Innovation Medical Technology Co., LtdINDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06658587 | A Novel Serological Risk Model for Early Non-invasive Diagnosis of Cholangiocarcinoma | not yet recruiting | — | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06656559 | Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Oct 24, 2024 | clinicaltrials |
| NCT06594289 | Evaluation of the Safety and Effectiveness of Pringle Method Combined With IVC Flow Limiting and Blocking Method in Laparoscopic Hepatectomy Based on Non-restrictive Fluid Therapy Strategy | recruiting | N/A | 220 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT05744219 | Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial(IRIS) | recruiting | Phase 3 | 338 | Jon UnossonOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT06353126 | DEB-TACE Prior to Liver Transplantation in the Treatment of HCC | recruiting | Phase 4 | 40 | RenJi HospitalOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06648525 | Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC | not yet recruiting | Phase 2 | 68 | Harbin Medical UniversityOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT02246634 | Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)(SERENADE) | recruiting | N/A | 282 | Imperial College LondonOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06647264 | A Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic Surgery | enrolling by invitation | — | 1,500 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04183712 | Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA | recruiting | Phase 2 | 102 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05882370 | TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study | recruiting | Phase 2 | 30 | Fei GaoOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06639971 | Therapeutic Effects of Immuno-targeted Therapy Combined With or Without RT for HCC(RIO-HCC) | not yet recruiting | — | 500 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06641453 | CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06643533 | Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004) | not yet recruiting | — | 15 | Fujian Provincial HospitalOTHER | 0 | Oct 16, 2024 | clinicaltrials |
| NCT06645067 | Assessment and Modulation of Energy Balance in Cachectic Patients Using Adapted Physical Activity(EMC2APA) | not yet recruiting | — | 10 | University of Rennes 2OTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06645314 | Study on the Safety and Efficacy of BST06 Injection in the Treatment of Advanced Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 16 | BioSyngen Pte LtdINDUSTRY | 0 | Oct 16, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT06569498 | Neoadjuvant Triple Therapy for Resectable HCC(TALENP001) | recruiting | — | 20 | Fujian Provincial HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06602011 | Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002) | recruiting | — | 20 | Fujian Provincial HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04195503 | Liver Transplant for Stable, Advanced Intrahepatic Cholangiocarcinoma | enrolling by invitation | N/A | 10 | University Health Network, TorontoOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05440864 | Durvalumab and Tremelimumab in Resectable HCC((NEOTOMA)) | recruiting | Phase 2 | 28 | University Health Network, TorontoOTHER | 3 | Oct 10, 2024 | clinicaltrials |
| NCT06623474 | Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma | recruiting | — | 900 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06632522 | Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients . | not yet recruiting | Phase 2 | 46 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06632886 | AI-Assisted Non-Contrast CT for Multi-Cancer Screening | recruiting | N/A | 1,000,000 | Guo ShiWeiOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06632093 | HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC | recruiting | — | 84 | First Hospital of China Medical UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06632106 | HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC | active not recruiting | — | 97 | First Hospital of China Medical UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06624098 | Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma | recruiting | N/A | 22 | Sun Yat-sen UniversityOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06617000 | A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related | recruiting | Phase 1 | 38 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06061276 | bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC | recruiting | N/A | 40 | Sun Yat-sen UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06464380 | Anti-cancer Potentiality of Saffron Against Hepatocellular Carcinoma | not yet recruiting | Phase 4 | 40 | Ain Shams UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06592612 | Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment | not yet recruiting | Phase 2 | 70 | Sun Yat-sen UniversityOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06593964 | TACE With Thermosensitive Nanogel Versus Embosphere for HCC | recruiting | N/A | 188 | Zhongda HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 20, 2024source: clinicaltrials